Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

749.51 +11.51 (+1.56%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
42 43 Next >
FDA Rescinds Authorization For Regeneron, Eli Lilly COVID-19 Antibody Treatments: Here's Why
Antibody treatments made by Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Eli Lilly And Co (NYSE: LLY) are not likely to work against the Omicron variant of COVID-19 and their... 
Via Benzinga
Analysis: Why Is It So Difficult To Obtain COVID-19 Monoclonal Antibody Treatments?
The demand for monoclonal antibody treatments to help in the recovery of COVID-19 patients has outpaced the supply, and this situation runs the risk of becoming more acute as... 
Via Benzinga
Second Dupixent Phase 3 Trial Confirms Significant Improvements In Inflammatory Skin Disease
Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have announced data from the second Phase 3 trial of Dupixent (dupilumab) in... 
Via Benzinga
The Daily Biotech Pulse: Gamida Gains On Positive Regulatory Development, Orphazyme & ADMA Preannouncements, ImmunityBio & Leap Present Positive Data
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Orphazyme Preannounces Positive FY21 Results Orphazyme A/S (NASDAQ: ORPH)... 
Via Benzinga
Regeneron Announces FDA Accepts For Review Libtayo In Combination With Chemotherapy For First-Line Treatment Of Advanced NSCLC
Regeneron Announces FDA Accepts For Review Libtayo In Combination With Chemotherapy For First-Line Treatment Of Advanced NSCLC 
Via Benzinga
WHO Recommends Glaxo, Eli Lilly Drugs For COVID-19 Treatment Amid Omicron Surge
An expert panel at the World Health Organization (WHO) recommended the use of treatments developed by Eli Lilly And Co (NYSE: LLY) and GlaxoSmithKline Plc... 
Via Benzinga
Connect Biopharma's Latest Dermatitis Drug Update Fails to Pump Up Shares
Key takeaways: Loss-making Connect Biopharma says Phase 3 clinical trials of its CBP-201 drug for atopic dermatitis will begin in second half of this year Connect Biopharma... 
Via Benzinga
The Journey To Rewrite Human DNA Is About To Get Wild, Thanks To Pfizer, Bayer, Intellia And Other CRISPR stocks
Big Pharma is paying attention to CRISPR stocks. Could that alight shares this year? 
Via Investor's Business Daily
Why JPMorgan Is Among Rob Sechan's Top Picks For 2022
With the Federal Reserve having suggested that rates are likely headed higher this year, financials have been an area of focus for investors.&... 
Via Benzinga
Why This Pfizer, Regeneron Analyst Has Contrasting Recommendations For The COVID Stock Plays
An analyst at BofA Securities on Wednesday shared a pair trade idea in the large-cap pharma space. The Biopharma Analyst: 
Via Benzinga
Market Briefing For Wednesday, Jan. 5
Rising interest rates have yet to spark overt action by the Fed nor yet to cool-off the hot real estate market. However, the Nasdaq was hit hard, presumably as the 10-year rallied. 
Via Talk Markets
Global Alzheimer’s Disease Therapeutics Market Projected To Generate Revenue Of $9.97 Billion By 2028
Palm Beach, FL –January 4, 2022 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease is a degenerative, progressive ailment that attacks the brain’s nerve cells, resulting in memory loss,... 
Via FinancialNewsMedia
Exposures COVID-19
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2022
Upgrades According to TD Securities, the prior rating for Canada Goose Holdings Inc (NYSE: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 3, 2022
Upgrades For nVent Electric PLC (NYSE:NVT), Vertica... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates
Regulatory decisions by the U.S. Food and Drug Administration in December turned out to be mostly positive. Among the treatment options that were greenlighted in the month were... 
Via Benzinga
Healthcare Stocks Are Winners And Provide Diversification To Your Portfolio
As we have written their year many times speculative small cap biotechs have not done well in 2021 since they peaked in February. 
Via Talk Markets
Two Paths to End the Pandemic but the Hybrid Approach Looks Dominant
Pfizer (NYSE: PFE) is arguably one of the biggest leaders in COVID-19 technology, whether it’s their vaccine or their newly approved oral antiviral called Paxlovid. The... 
Via Benzinga
3 Cathie Wood Stocks To Buy On The Dip
Institutional investor Cathie Wood gained popularity after her ETFs generated big gains last year. Wood asserted recently that her stocks are poised for long-term gains. Hence, we think investing in... 
Via Talk Markets
Biotech Playbook 2021 Part 2: Rotation Rally Brings Relief after FED Pivot
The new aggressive Fed taper combined with a rise in interest rates for 2022 adds a new element of risk to portfolio management. Monetary policy is a headwind for 2022. 
Via Talk Markets
Adagio Therapeutics Continues Its Wild Ride — How Two Tests Led To A Triple-Digit Gain
Two tests from independent labs suggest Adagio's antibody could still target omicron. 
Via Investor's Business Daily
AstraZeneca's COVID-19 Antibody Effective Against Omicron Variant
New preclinical data released by AstraZeneca Plc (NASDAQ: AZN) shows that its long-acting antibody Evusheld (tixagevimab co-packaged with cilgavimab) works against... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2021
Upgrades B of A Securities upgraded the previous rating for ONE Gas Inc (NYSE: 
Via Benzinga
Biotech Playbook 2021: No Help From Small Caps In Q4
Mid-cap stock picks have done better today but are way off their 2021 highs. Cryoport and Veracyte are still up and look better technically. Quidel was up 5.48% today on Omicron concerns globally but... 
Via Talk Markets
Composite Rating For Regeneron Stock Rises To 96
Regeneron stock saw its IBD SmartSelect Composite Rating rise to 96 Thursday, up from 93 the day before for the New York firm. 
Via Investor's Business Daily
Novartis Reveals Two Year Results From Beovu Trial In Diabetic Macular Edema Patients
Novartis AG (NYSE: NVS) has reported the first interpretable results from year two (week 100) of the Phase 3 KESTREL study of Beovu (brolucizumab) 6 mg in patients... 
Via Benzinga
4 Low-Beta Stocks To Buy For A Volatile Market
Global economic uncertainty, inflationary pressure, a disappointing jobs report, and concerns around the COVID-19 Omicron variant are fostering market volatility. So, against this backdrop, we think it... 
Via Talk Markets
Exposures COVID-19
2 Big Stock Bets That Are Insiders Are Buying Now
Reddit users picked their favorite biotech stocks, and all of them have fallen this year. The insiders have a different buying strategy. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021
Upgrades According to BMO Capital, the prior rating for Nuvei Corp (NASDAQ: 
Via Benzinga
How Did Healthcare Stocks Perform Over This Volatile Month?
It’s been a rough month for small-cap biotech stocks amidst a general correction in the market which brought general indices down about 10%. 
Via Talk Markets
Where Regeneron Pharmaceuticals Stands With Analysts
Analysts have provided the following ratings for Regeneron Pharmaceuticals (NASDAQ: 
Via Benzinga
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
42 43 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.